Medicines appraisal cards

Medicines appraisal cards have been developed for the Guidelines audience to announce new recommendations from the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and the All Wales Medicines Strategy Group (AWMSG). Items may contain pharmaceutical promotional information.

Final version_Sixmo SMC card

Sixmo®▼ (buprenorphine) 74.2mg implant SMC2372

Commissioned and funded by Accord Healthcare Limited

The production of this Guidelines card has been commissioned by Accord Healthcare Limited.
View adverse event reporting and prescribing information
UK-03735 April 2022

Klisyri (tirbanibulin) SMC card - digital

Tirbanibulin 10mg/g ointment (Klisyri®▼) SMC2395

Commissioned by Almirall Ltd

The production of this Guidelines card has been commissioned by Almirall Ltd.
View prescribing and adverse event reporting information
IE-KLI-2100016 December 2021

Daiichi Sankyo logo

Bempedoic acid (Nilemdo®▼) and Bempedoic acid / ezetimibe (Nustendi®▼) SMC card

Commissioned and funded by Daiichi Sankyo

The production of this Guidelines card has been commissioned and funded by Daiichi Sankyo UK. This content is for healthcare professionals only.
View Bempedoic acid (Nilemdo®) & Bempedoic acid and ezetimibe (Nustendi®) prescribing and adverse event reporting information
BEM/21/0777 December 2021

20201002 Rizmoic TA card V5 image

NICE Technology Appraisal 651: Naldemedine ▼ for treating opioid‑induced constipation

Commissioned by Sandoz Limited

The production and printing of this Guidelines summary card has been commissioned by Sandoz Ltd. Information intended for UK healthcare professionals only.
View prescribing information

UK/P/RZM/20-0016c October 2020